Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15389662 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HTTTSHRCA1CA2 | |
| SCHEMBL15461578 | 0.78 | TSHR (0.52) | ALDH1A1HTTTSHRCA1CA2 | |
| SCHEMBL30950539 | 0.76 | ALDH1A1 (0.40) | ALDH1A1HTTTSHRCA1CA2 | |
| SCHEMBL18512516 | 0.76 | ALDH1A1 (0.40) | ALDH1A1HTTTSHRCA1CA2 | |
| SCHEMBL106062 | 0.74 | TSHR (0.50) | ALDH1A1HTTGABRA1GABRB2TSHR | |
| SCHEMBL20091677 | 0.74 | L3MBTL1 (0.39) | ALDH1A1HTTGABRA1GABRB2TSHR | |
| SCHEMBL20073215 | 0.74 | ALDH1A1 (0.38) | ALDH1A1HTTNR3C1TSHRCA1 | |
| SCHEMBL20155929 | 0.73 | ALDH1A1 (0.41) | ALDH1A1HTTGABRA1GABRB2NR3C1 | |
| SCHEMBL7790350 | 0.73 | GABRA1 (0.41) | ALDH1A1HTTGABRA1GABRB2TSHR | |
| SCHEMBL11524213 | 0.73 | GABRA1 (0.41) | GABRA1GABRB2TSHRHSD11B1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885HTT 1087/4885GABRA1 2223/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885HTT 1087/4885GABRA1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.